GRNA - GRNA STOCK NEWS

GreenLight Biosciences Holdings, PBC is set to complete its merger with SW MergerCo, Inc. and SW ParentCo, Inc. on July 20, 2023. Following the merger, GreenLight's common stock will no longer be traded on NASDAQ. A total of 18,791,264 shares of GreenLight common stock were tendered and not withdrawn, representing approximately 60.4% of outstanding shares. Each remaining share will be converted into the right to receive $0.30 in cash.

On March 30, 2023, GreenLight Biosciences (Nasdaq: GRNA) announced it has received a non-binding offer from Fall Line Endurance Fund, L.P. to acquire all outstanding shares of the company at $0.60 per share. This proposed transaction is subject to various conditions including due diligence and negotiations. GreenLight's Board, via a special committee, will evaluate this offer along with other alternatives. There is no guarantee that a definitive agreement will be reached. GreenLight specializes in RNA technology for human health and agriculture, currently developing pre-clinical products and early-stage agricultural solutions.

GreenLight Biosciences (Nasdaq: GRNA) announced key updates and financial results for Q4 and full year 2022. The company is awaiting EPA approval for two agriculture solutions: Calantha™ for potatoes and a honeybee protection solution. It is also advancing its Covid vaccine strategy with a pan-sarbecovirus candidate. Financially, GreenLight reported cash and equivalents of $68.1 million, up from $31.4 million in 2021, but incurred a net loss of $38.8 million in Q4 2022 compared to $34.7 million in Q4 2021. R&D expenses rose to $32.4 million. Guidance indicates sufficiency of current cash through Q2 2023.

GreenLight Biosciences (Nasdaq: GRNA) has highlighted its R&D pipeline during its Human Health R&D Day. The company is focusing on developing mRNA-based vaccines for infectious diseases and oncology treatments, especially in lower- and middle-income countries. They are prioritizing a universal pan-sarbecovirus vaccine over a previously planned monovalent COVID-19 vaccine, leveraging preclinical data from its shingles vaccine candidate, which exhibits strong antibody and T-cell responses. A partnership with EpiVax Therapeutics aims to create personalized mRNA cancer vaccines, initially targeting bladder cancer. The company aims for sustainable global vaccine access.

On March 7, 2023, GreenLight Biosciences (Nasdaq: GRNA) presented its Plant Health R&D strategy, emphasizing the development of double-stranded RNA (dsRNA) solutions for sustainable agriculture. CEO Andrey Zarur highlighted the company's commitment to addressing global food security challenges through innovative crop protection technologies. The company aims to tap into the $39 billion insecticides and $35.72 billion herbicides markets, addressing issues like pest resistance and regulatory challenges. Key updates include the anticipated launch of Calantha™, submission of a registration dossier for its RNA solution targeting varroa destructor mite, and promising in-field data on plant disease control.

GreenLight Biosciences (Nasdaq: GRNA) will host a two-part R&D Day Series for analysts and investors, focusing on plant and human health. Session One is scheduled for March 7, 2023, from 10:30 a.m. – 1:30 p.m. ET at the North Carolina Biotech Center. Session Two will take place on March 9, 2023, at the company's Lexington, MA headquarters. Both events will provide updates on GreenLight's R&D strategy and progress. Live webcasts are available via the Investor section of their website, with replays accessible for 30 days afterward.